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Abstract
Background: Some members of the Protein 4.1 superfamily are believed to be involved in cell proliferation and
growth, or in the regulation of these processes. While the expression levels of two members of this family, radixin
and moesin, have been studied in many tumor types, to our knowledge they have not been investigated in
prostate cancer.
Methods: Tissue microarrays were immunohistochemically stained for either radixin or moesin, with the staining
intensities subsequently quantified and statistically analyzed using One-Way ANOVA or nonparametric equivalent
with subsequent Student-Newman-Keuls tests for multiple comparisons. There were 11 cases of normal donor
prostates (NDP), 14 cases of benign prostatic hyperplasia (BPH), 23 cases of high-grade prostatic intraepithelial
neoplasia (HGPIN), 88 cases of prostatic adenocarcinoma (PCa), and 25 cases of normal tissue adjacent to
adenocarcinoma (NAC) analyzed in the microarrays.
Results: NDP, BPH, and HGPIN had higher absolute staining scores for radixin than PCa and NAC, but with a
significant difference observed between only HGPIN and PCa (p = < 0.001) and HGPIN and NAC (p = 0.001). In the
moesin-stained specimens, PCa, NAC, HGPIN, and BPH all received absolute higher staining scores than NDP, but
the differences were not significant. Stage 4 moesin-stained PCa had a significantly reduced staining intensity
compared to Stage 2 (p = 0.003).
Conclusions: To our knowledge, these studies represent the first reports on the expression profiles of radixin and
moesin in prostatic adenocarcinoma. The current study has shown that there were statistically significant
differences observed between HGPIN and PCa and HGPIN and NAC in terms of radixin expression. The differences
in the moesin profiles by tissue type were not statistically significant. Additional larger studies with these markers
may further elucidate their potential roles in prostatic neoplasia progression.
Background
Prostate adenocarcinoma is the second most commonly
diagnosed cancer in American males, trailing only skin
malignancies. During 2010 alone, it is projected that
217,730 new cases of prostate adenocarcinoma will be
diagnosed in the United States. During the same year,
32,050 deaths attributable to this cancer are expected to
occur [1]. Understanding the cellular protein expression
patterns associated with prostate adenocarcinoma may
provide greater insight into the processes of prostatic
neoplastic growth and dissemination, as well as allow
for the identification of novel prognostic biomarkers
and therapeutic targets.
The Protein 4.1 superfamily is one of current interest in
this regard. Many of this family’s proteins serve to cross-
link components of the cellular plasma membrane to the
internal cytoskeleton [2,3], and have therefore been postu-
lated to play a role in the processes of cellular adhesion
[2,4] and, in some instances, growth and proliferation and
the regulation of these processes [3,5,6]. Strong cytoplas-
mic immunohistochemical staining for ezrin, a member of
the ezrin-radixin-moesin (ERM) subfamily of Protein 4.1
[6], has been associated with decreased survival in upper
aerodigestive tract squamous cell carcinoma [7]. Addition-
ally, ezrin positivity has been associated with decreased
survival rates and incidence-free periods in hepatocellular
carcinoma [8]. In prostatic adenocarcinoma specifically, its
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ferentiation [9].
Conversely, loss of Protein 4.1B, another member of
the same superfamily [3], has been shown to lead to an
enhanced metastatic capacity during the induction of
human adenocarcinoma PC-3 cells into immunodefi-
cient mice [10]. These studies support the conclusion
that not all members of this superfamily have the same
effects on carcinogenic processes.
Two members of this superfamily whose prostatic tis-
sue expression has not been well characterized in the lit-
erature are radixin and moesin. Radixin is an ~80 kDa
protein [11] that has been shown to be down regulated
in some cases of lung adenocarcinoma [12]. Addition-
ally, its chromosomal location, 11q23, has shown a loss
of heterozygosity in select incidences of lung, breast,
ovarian, and colon cancer [13]. Moesin, a 78kDa protein
[14], has been associated with decreased survival in oral
squamous cell carcinoma when a cytoplasmic distribu-
tion pattern was observed [15]. Moesin-positive cases of
pancreatic adenocarcinoma have been associated with
shorter survival times than moesin-negative cases [16],
with moesin-positive tumors demonstrating higher his-
topathologic grades and perineural and lymphovascular
invasion rates [17]. Despite this, it, like radixin, has been
shown to be down regulated in select cases of lung
adenocarcinoma [12].
In this study, the immunohistochemical staining inten-
sity of both radixin and moesin was examined in tissue
microarrays of normal donor prostates (NDP), benign
prostatic hyperplasia (BPH), high-grade prostatic intrae-
pithelial neoplasia (HGPIN), prostatic adenocarcinoma
(PCa), and normal tissue adjacent to prostatic adenocar-
cinoma (NAC). Low grade prostatic intraepithelial neo-
plasia was not studied both because the diagnosis is
subjective and because it lacks clinical relevance. In gen-
eral, the percentage of cases of HGPIN that feature pro-
static adenocarcinoma on rebiopsy is 30% [18]. No
specimens of HGPIN included in this study were diag-
nosed at the time as containing PCa.
Methods
Preparation of Tissue Microarray Blocks
Two sets of tissue microarray (TMA) blocks were con-
structed using specimens located in the Health Sciences
Tissue Bank at the University of Pittsburgh Medical
Center. All specimens were originally obtained through
either a radical prostatectomy, transurethral resection of
the prostate, or via a needle biopsy of the prostate, with
the majority obtained using the first two methods.
Cores were taken from the appropriate case specific par-
affin-embedded tissue blocks and assembled into new
TMAs as previously described [19]. Due to variations in
TMA processing, 11 cases of NDP, 14 cases of BPH, 23
cases of HGPIN, 87 cases of PCa, and 24 cases of NAC
were analyzed for radixin staining intensity. Eleven cases
of NDP, 12 cases of BPH, 23 cases of HGPIN, 88 cases
of PCa, and 25 cases of NAC were analyzed for moesin
staining intensity. While every effort was made to
include all of the cases in this study, processing artifacts
within some of the TMAs cores made them unscorable,
hence resulting in a difference in the numbers of cases
between the two stains. For each set, at least four cores
were taken from each case to ensure adequate sampling.
Each case was included only if at least three cores were
processed completely enough to be scored.
Immunohistochemistry
Each TMA block was deparaffinized and subsequently
rehydrated with incremental ethanol concentrations.
Decloaker was then used for heat induced epitope
retrieval, followed by a 5 minute TBS buffer rinse. The
slides were then placed in a Dako Autostainer. One set
of TMAs was stained with anti-radixin C-15 (working
dilution 1:200), a polyclonal goat antibody (Catalogue #
sc-6408) from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). The other set was stained with primary anti-
moesin C-15 (working dilution 1:50), a polyclonal goat
antibody (Catalogue # sc-6410) from Santa Cruz Bio-
technology (Santa Cruz, CA, USA). Immunolabeling was
conducted using Vectastain Elite Goat IgG -ABC Kit
(Avidin/Biotin) from Vector Laboratories (Burlingame,
CA, USA). Slides were counterstained with hematoxylin
before being coverslipped.
Scoring of Slides
Staining for both radixin and moesin was assessed in the
cytoplasm of the cells of the prostatic glandular epithe-
lium. Slides were scored on a scale of staining intensity,
with 0 representing no staining, 1 representing weak
staining, 2 representing moderate staining, and 3 repre-
senting strong staining. The intensity was then summed
with the percentage of the core stained multiplied by
four. In cores where more than one staining intensity
was significantly represented, the average score for the
core was calculated. This scoring procedure is adapted
from a scoring protocol previously used by Parwani,
et al. [20] The mean score for each case was then deter-
mined. Finally, the mean scores were obtained for each
type of prostatic tissue represented. Means by Gleason
score and tumor stage, where available, were also
obtained. The Clinical TNM, as opposed to the Patholo-
gic TNM, staging classification was used to assess the
specimens. All means were reported with standard error.
One Way ANOVA analysis or Kruskal-Wallis tests were
used to analyze the groups (a = 0.05). Two different statisti-
cal tests were used in this study, depending on whether the
data in specific comparison met the statistical assumptions
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between the groups, both necessary to perform a para-
metric analysis. If not, this necessitated a non-parametric
Kruskal-Wallis test. Subsequent Student-Newman-Keuls
tests for multiple comparisons were conducted to analyze
differences (a = 0.05).
Photomicrographs of tissue cores were taken using an
Olympus BX51 microscope using Spot Advanced V4.6
(Diagnostic Instruments, Inc.) software. All images were
taken at 10x.This study received exempt approval
(PRO08040368) from the University of Pittsburgh Insti-
tutional Review Board. This approval and abiding by the
guidelines for usage of specimens from the Health
Sciences Tissue Bank at the University of Pittsburgh per-
mitted the use of all specimens included in this study.
Results
Age Classification
The average ages and standard deviations of the patients
whose specimens were included in the TMAs at the
time of specimen retrieval were 66.7 ± 6.2 for PCa, 66.9
± 8.31 for BPH, 32.1 ± 12.7 for NDP, 67.9 ± 5.25 for
NAC, and 66.5 ± 5.7 for HGPIN.
Staining Intensities for Radixin
The mean staining scores for NDP, BPH, HGPIN, PCa, and
NAC in the radixin-stained TMAs were 3.34 ± 1.29, 3.27 ±
0.12, 3.51 ± 0.18, 2.79 ± 0.08, 2.72 ± 0.13 (Figure 1).
AO n e - W a yA N O V A( p=<0 . 0 0 1 ) ,w i t hs u b s e q u e n t
Student-Newman-Keuls tests for multiple comparisons,
showed significant differences between HGPIN and NAC
(p = 0.001) and HGPIN and PCa (p = < 0.001).
When classified by Gleason score, the mean staining
scores for the radixin-stained TMAs were score 6 or
less, 2.67 ± 0.24 (n = 10), score 7, 2.91 ± 0.12 (n = 42),
and score 8 or higher, 2.68 ± 0.12 (n = 35) (Figure 2).
A resultant One-Way ANOVA showed no significant
differences (p = 0.355). When classified by tumor stage,
the mean scores for the radixin-stained TMAs were
stage 2 or less, 2.79 ± 0.14 (n = 35), stage 3, 2.67 ± 0.14
Figure 1 Mean radixin staining intensity by prostatic tissue type. Significant differences are seen between prostatic intraepithelial neoplasia
and prostatic adenocarcinoma (p = < 0.001) and normal tissue adjacent to prostatic adenocarcinoma (p = 0.001). The asterisk (*) and the dagger
(†) are used to signify the tissue types that are significantly different.
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A resultant One-Way ANOVA showed no significant
differences (p = 0.737).
Staining Intensities for Moesin
The mean staining scores for NDP, BPH, HGPIN, PCa,
and NAC in the moesin-stained TMAs were 3.15 ±
0.06, 3.39 ± 0.09, 3.49 + 0.11, 3.40 + 0.09, 3.43 + 0.08
(Figure 4). A Kruskal-Wallis test showed no significant
differences between the moesin-stained groups
(p = 0.152).
When classified by Gleason score, the mean staining
scores for the moesin-stained TMAs were score 6 or
less, 3.53 ± 0.16, score 7, 3.40 ± 0.09, and score 8 or
higher, 3.37 ± 0.08 (Figure 5). A resultant One-Way
ANOVA showed no significant differences (p = 0.719).
When classified by stage, the mean staining scores for
the moesin-stained TMAs were stage 2 or less, 3.62 ±
0.073, stage 3, 3.33 ± 0.10, and stage 4, 3.17 + 0.11
(Figure 6). A resultant One-Way ANOVA (p = 0.003)
and subsequent Student-Newman-Keuls test for multiple
comparisons showed a significant decrease in Stage 4
staining compared to Stage 2 (p = 0.003).
Representative photomicrographs of the TMAs are
s h o w ni nF i g u r e s7a n d8 .R a d i x i ns t a i n i n gw a sd i f f u s e
and cytoplasmic. Moesin staining was also diffuse and
cytoplasmic, but was more granular in appearance than
radixin.
Discussion
In the radixin-stained specimens, the average intensities
were highest in the HGPIN specimens, followed by






























Figure 2 Mean radixin staining intensity by Gleason score. Mean radixin staining intensity by Gleason score. No significant differences were
seen in this classification (p = 0.938).






























Figure 3 Mean radixin staining intensity by carcinoma stage. No significant differences were seen in this classification (p = 0.737).
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Figure 5 Mean moesin staining intensity by Gleason score. No significant differences were seen in this classification (p = 0.719).
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the lowest levels of staining (Figure 1). These absolute
differences may support the notion that radixin is down
regulated in prostatic adenocarcinoma, given that the
lowest intensities were from specimens containing ade-
nocarcinoma, although a One-Way ANOVA with subse-
quent Student-Newman-Keuls analysis revealed that
a significant difference was only observed between
HGPIN and NAC (p = 0.001) and HGPIN and PCa (p =
<0.001). There are several possible reasons for our find-
ing that specimens of carcinoma have less average stain-
ing than HGPIN. This may represent the unique
physiological progression of radixin from the pre-
neoplastic state to the neoplastic state. Another possibi-
lity is that within specimens of HGPIN, there can be a
wide spectrum of histologic findings. More specifically,
this means that in addition to glands demonstrating
HGPIN, there may also be some elements of co-accom-
panying normal histological architecture, which may
assist in imparting a higher staining score on these spe-
cimens. This may be true, as previous work has shown
radixin to be down regulated in some instances of lungs
cancer in comparison to non-tumor lung tissue [12].
The finding that the difference between NDP and PCa
specimens was not significant, then, may be a reflection
of the sample size of NDPs available for study. As there
were fewer NDPs, the natural baseline variability among
their expression levels may have had a greater impact in
precluding statistical significance despite the absolute
staining of NDP being higher than PCa. No significant
differences were seen by Gleason score or stage in speci-
mens of prostatic adenocarcinoma (Figure 2 and 3).
In the moesin-stained specimens, the average staining
intensities were highest in the HGPIN specimens,
followed by NAC, PCa, BPH, and lastly, NDP (Figure 4).
No significant differences were seen amongst the groups
using a Kruskal-Wallis test (p = 0.152). No significant
differences were seen when the adenocarcinoma speci-
mens were stratified by Gleason score. A significant dif-
ference was noted between Stage 2 and Stage 4 staining
(p = 0.003). The finding that moesin appears to be
down regulated from Stage 2 to Stage 4 may seem coun-
terintuitive, as moesin-positive tumors have been shown
to demonstrate higher perineural invasion rates in pan-
creatic adenocarcinoma [17]. However, moesin expres-
sion patterns can vary by cancer type, as moesin, like
radixin, has been shown to be down regulated in cases
of lung cancer [12]. Moreover, it is possible that this
finding may reflect a late stage change in tumor
physiology.
Conclusions
These results provide a basis for the characterization of
radixin and moesin expression patterns in prostatic ade-
nocarcinoma. More specifically, given that a difference
was observed between HGPIN and PCa, this may indi-
cate that radixin has the potential to be a clinically use-
ful biomarker, but larger studies still need to be
conducted before any definitive conclusions can be
made. Future studies could also look at the expression
of radixin in specimens of metastatic prostatic adenocar-
cinoma in order to determine if radixin is a clinically
useful marker to predict the risk of metastasis.
While moesin staining was higher in specimens of PCa
than in normal tissue, the staining scores were also higher
in HGPIN than they were in PCa, which makes moesin
unlikely to be a useful clinical biomarker to diagnose pros-
tate cancer based upon this study. While a significant































Figure 6 Mean moesin staining intensity by carcinoma stage. A significant decrease between Stage 2 and Stage 4 staining was observed
(p = 0.003).
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and Stage 4 PCas, the actual staining intensities were close
in absolute terms (Figure 6). While this difference may
reflect a change in physiology in the tissues between
stages, additional larger studies will need to be conducted
to determine its ability to correlate with stage prior to any
clinical implementation.
One proposed model for cell proliferation involving
t h eE R Ms u b f a m i l yo fP r o t e i n4 . 1i n d i c a t e sr o l e sf o r
both growth promoters and tumor suppressors within
the family. In this model, CD44, a glycoprotein, is
believed to interact with growth promoting factors,
with ERM proteins being phosphorylated and binding
to CD44 in the process, leading to a pro-proliferative
state [6].
Merlin (moesin-ezrin-radixin-like protein), the product
of the neurofibromatosis type 2 (NF2) gene, is another
member of the Protein 4.1 superfamily that has an estab-
lished function as a schwannoma and meningioma tumor
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Figure 7 Photomicrographs of radixin TMA cores. Representative immunohistochemical staining for radixin in A) normal donor prostate
B) high-grade prostatic intraepithelial neoplasia and C) prostatic adenocarcinoma. Radixin staining was diffuse and cytoplasmic. High-grade
prostatic intraepithelial neoplasia had a significantly higher staining score than prostatic adenocarcinoma (p < 0.001).
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[21]. Conversely, it has been proposed to bind CD44
when not phosphorylated, suppressing growth, and is
believed to be active in states of high cell densities [5,6].
This is especially interesting when viewed in the light
that merlin was shown to be inactivated by constitutive
phosphorylation in DU145 line prostate cancer cells [22].
As more studies are conducted in this area, possibly
looking at the expression of these markers in metastatic
specimens, more definitive roles for the behavior of
radixin and moesin in prostate cancer may be discovered,
possibly expanding on existing models regarding cell
growth and proliferation, and the involvement of mem-
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Figure 8 Photomicrographs of moesin TMA cores. Representative immunohistochemical staining for moesin is featured in A) normal tissue
adjacent to prostatic adenocarcinoma B) high-grade prostatic intraepithelial neoplasia and C) prostatic adenocarcinoma. Moesin staining was
also diffuse and cytoplasmic, but was more granular in appearance than radixin. There were no significant differences in staining among the
tissue types (p = 0.0152).
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